253 research outputs found
New observations on Saturnella saturnus (Steinecke) Fott: the first British record of a little-known enigmatic ‘green’ alga
Saturnella saturnus was discovered in March 2014 in open-water pools on blanket peatland at the Moor House - Upper Teesdale National Nature Reserve, straddling Cumbria and County Durham in NE England. This is the first record for the British Isles of a little-known alga known previously only from a few peat bog areas, mainly in mainland Europe. The literature is reviewed and new observations presented on its morphology and reproduction based on LM examination of living cells. New observations on the chloroplast structure and cytoplasmic inclusions (especially oil droplets) are discussed in relation to the findings of earlier studies. Doubt attaches as whether it is a chlorophyte or a xanthophyte and the identity of small spherical inclusions that have been frequently interpreted as autospores. It occurs in Upper Teesdale in pools that are that are small, relatively newly formed and mostly well-oxygenated. Also discussed is its relationship to Trochiscia, another coloniser of peatland pools. Photographic images are presented for the first time and comments made on its ecology in the context of blanket bog conservation projects and apparent rarity
Recommended from our members
Inhibition of adenovirus serotype 14 infection by octadecyloxyethyl esters of (S)-[(3-hydroxy-2-phosphonomethoxy)propyl]- nucleosides in vitro.
On September 22, 2008, a physician on Prince of Wales Island, Alaska, notified the Alaska Department of Health and Social Services (ADHSS) of an unusually high number of adult patients with recently diagnosed pneumonia (n = 10), including three persons who required hospitalization and one who died. ADHSS and CDC conducted an investigation to determine the cause and distribution of the outbreak, identify risk factors for hospitalization, and implement control measures. This report summarizes the results of that investigation, which found that the outbreak was caused by adenovirus 14 (Ad14), an emerging adenovirus serotype in the United States that is associated with a higher rate of severe illness compared with other adenoviruses. Among the 46 cases identified in the outbreak from September 1 through October 27, 2008, the most frequently observed characteristics included the following: male (70%), Alaska Native (61%), underlying pulmonary disease (44%), aged > or = 65 years (26%), and current smoker (48%). Patients aged > or = 65 years had a fivefold increased risk for hospitalization. The most commonly reported symptoms were cough (100%), shortness of breath (87%), and fever (74%). Of the 11 hospitalized patients, three required intensive care, and one required mechanical ventilation. One death was reported. Ad14 isolates obtained during the outbreak were identical genetically to those in recent community-acquired outbreaks in the United States which suggests the emergence of a new, and possibly more virulent Ad14 variant. Clinicians should consider Ad14 infection in the differential diagnosis for patients with community-acquired pneumonia, particularly when unexplained clusters of severe respiratory infections are detected
The Australian Vascular Epiphytes: Flora & Ecology
Firstly, recent literature dealing with the systematics and ecology of vascular epiphytes is reviewed, as are a selection of older key papers. The classification and terminology of vascular epiphytes is briefly reviewed and discussed and the system used here is delineated; tenns are defined, including a ntnnber of new and previously ill-defined ones. The Australian vascular epiphyte flora is then described in a tabulated list and in a more detailed, illustrated descriptive key (Appendix 1). The flora is next discussed in relation to its taxonomic composition, diversity and affinities biogeography, life forms and physiognomic forms, and diaspore dispersal methods; these are also briefly related to basic ecology of the groups. Next, physical ecological factors of epiphyte environments in Australia are investigated. This includes discussion of continental macroclimate and its bearing on the distribution of epiphyte-favoured vegetation types, particularly rainforests, and investigation of microclimate components at different levels within selected sites in five different rainforest subformations of the subtropics. The results of this show that microsites near the canopy are considerably brighter, drier and more temperature-extreme than are those near the tree trunk bases. Beginning with a review of relevant works, the synecology of epiphytes is next discussed and the system of study for use here is outlined. The epiphytic vegetation of five subtropical sites (those mentioned above) and a tropical one, are investigated using this system which involves marked plots and the recording of all trees and epiphytes within them. The data derived from these are used in conjunction with that mentioned above and other observations for comparison and discussion of such topics as epiphyte floristic diversity, population density, vegetational complexity, occurrence of different epiphyte forms, specificity of epiphyte/phorophyte relationships, phorophyte axeny and epiphyte-proneness, allelopathy and phorophyte age ef~ect. Observations and review on nest-epiphytes and succession are discussed. Some basic functions of CAM in two epiphytic orchids were investigated under field conditions and the results are discussed in relation to its adaptive significance; the results of a survey of CAM in the Australian epiphytes are discussed and from this and the former, it is concluded that CAM is a very important water-conserving mechanism particularly to the heliophilous epiphytes. Relevant literature is reviewed. It is generally concluded from all of the above that epiphytism has been developed by small, slow-growing plants to avoid competition for light and in doing so, they have had to concomitantly adapt to water-stress and nutrient deficiency
The Grizzly, April 25, 2000
District Attorney Speaks Out Against Hazing • The Great Re-Election Debate • Frameography: Another Fresh New Face in Collegeville • Ursinus\u27 Honor Societies Members \u2700 • Religion Rules at Upsilon Phi Delta Discussion • Blues in Full Bloom at Flowers\u27 Performance • Student Art Achievement at Ursinus College • Letter to the Editor • Softball Squad Ranked Second in the NCAA East Region • Ursinus Lacrosse Thrashes Mawrters in 21-4 Romp • Bears Swing Into First Place Over Johns Hopkins • UC Field Hockey: Building for the Future • Track Sprints Toward Conference Champs • Fisher Takes CC by Stormhttps://digitalcommons.ursinus.edu/grizzlynews/1467/thumbnail.jp
Phase 1 study of Intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
Background: Enadenotucirev (formerly ColoAd1) is a tumor-selective chimeric adenovirus with demonstrated preclinical activity. This phase 1 Mechanism of Action study assessed intravenous (IV) delivery of enadenotucirev in patients with resectable colorectal cancer (CRC), non-small-cell lung cancer (NSCLC), urothelial cell cancer (UCC), and renal cell cancer (RCC) with a comparator intratumoral (IT) dosed CRC patient cohort. Methods: seventeen patients scheduled for primary tumor resection were enrolled. IT injection of enadenotucirev (CRC only) was administered as a single dose (≤ 3 × 1011 viral particles [vp]) on day 1, followed by resection during days 8-15. IV infusion of enadenotucirev was administered by three separate doses (1 × 1012 vp) on days 1, 3, and 5, followed by resection during days 8-15 (CRC) or days 10-25 (NSCLC, UCC, and RCC). Enadenotucirev activity was measured using immunohistochemical staining of nuclear viral hexon and quantitative polymerase chain reaction for viral genomic DNA. Results: delivery of enadenotucirev was observed in most tumor samples following IV infusion, with little or no demonstrable activity in normal tissue. This virus delivery (by both IV and IT dosing) was accompanied by high local CD8+ cell infiltration in 80% of tested tumor samples, suggesting a potential enadenotucirev-driven immune response. Both methods of enadenotucirev delivery were well tolerated, with no treatment-associated serious adverse events. Conclusions: this study provides key delivery and feasibility data to support the use of IV infusion of enadenotucirev, or therapeutic transgene-bearing derivatives of it, in clinical trials across a range of epithelial tumors, including the ongoing combination study of enadenotucirev with the checkpoint inhibitor nivolumab. It also provides insights into the potential immune-stimulating properties of enadenotucirev. Trial registration: this MOA study was a phase 1, multicenter, non-randomized, open-label study to investigate the administration of enadenotucirev in a preoperative setting (ClinicalTrials.gov: NCT02053220)
The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design
Aims Cachexia, the wasting disorder associated with a wide
range of serious illnesses including cancer, is a major cause of morbidity and mortality. There is currently no widely approved therapeutic agent for treating or preventing
cancer-associated cachexia. Colorectal cancer and nonsmall
cell lung cancer have relatively high incidences of cachexia, approximately 28% and 34%, respectively.
Neurohormonal overactivity has been implicated in the
genesis and progression of cachexia and beta receptor
antagonism has been proposed as a potential therapy.
MT-102, a novel anabolic/catabolic transforming agent,
has a multi-functional effect upon three potential pharmacological targets in cancer cachexia, namely reduced
catabolism through non-selective β-blockade, reduced
fatigue, and thermogenesis through central 5-HT1a
antagonism and increased anabolism through partial β-2
receptor agonism.
Methods At least 132 male and female patients, aged
between 25 and 80 years with a confirmed diagnosis of
late-stage non-small cell lung cancer or colorectal cancer,
with cachexia will be randomised to either one of the two
MT-102 doses or placebo in a 3:1:2 ratio (MT-102
10 mg BD−1/MT-102 2.5 mg BD/placebo). Patients will
continue on study treatment for maximally 16 weeks. The
primary endpoint, to be analysed by assigned treatment
group, will be body weight change over 16 weeks. For this
endpoint, the study has 85% power (0.05% significance
level) to detect per 4-week period a mean change of −0.8 kg
in the placebo group and 0 kg in the high-dose MT-102
arm. The first patient was randomised in February 2011 and
patient recruitment is expected to continue until mid-2012.
Perspective The ACT-ONE trial is designed to test whether
the anabolic/catabolic transforming agent MT-102 will
positively impact on the rate of change of body weight in
cancer cachexia, thereby evaluating a novel therapeutic
strategy in this hitherto poorly treatable condition. A
separate ACT-TWO trial will recruit patients who complete
the ACT-ONE trial and remain on randomised double-blind
medication. Participants in ACT-TWO will be followed for
an additional period with a separate primary endpoint
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer
TP53 is the most frequently altered gene in head and neck squamous cell carcinoma, with mutations occurring in over two-thirds of cases, but the prognostic significance of these mutations remains elusive. In the current study, we evaluated a novel computational approach termed evolutionary action (EAp53) to stratify patients with tumors harboring TP53 mutations as high or low risk, and validated this system in both in vivo and in vitro models. Patients with high-risk TP53 mutations had the poorest survival outcomes and the shortest time to the development of distant metastases. Tumor cells expressing high-risk TP53 mutations were more invasive and tumorigenic and they exhibited a higher incidence of lung metastases. We also documented an association between the presence of high-risk mutations and decreased expression of TP53 target genes, highlighting key cellular pathways that are likely to be dysregulated by this subset of p53 mutations that confer particularly aggressive tumor behavior. Overall, our work validated EAp53 as a novel computational tool that may be useful in clinical prognosis of tumors harboring p53 mutations
Systemic AAV vectors for widespread and targeted gene delivery in rodents
We recently developed adeno-associated virus (AAV) capsids to facilitate efficient and noninvasive gene transfer to the central and peripheral nervous systems. However, a detailed protocol for generating and systemically delivering novel AAV variants was not previously available. In this protocol, we describe how to produce and intravenously administer AAVs to adult mice to specifically label and/or genetically manipulate cells in the nervous system and organs, including the heart. The procedure comprises three separate stages: AAV production, intravenous delivery, and evaluation of transgene expression. The protocol spans 8 d, excluding the time required to assess gene expression, and can be readily adopted by researchers with basic molecular biology, cell culture, and animal work experience. We provide guidelines for experimental design and choice of the capsid, cargo, and viral dose appropriate for the experimental aims. The procedures outlined here are adaptable to diverse biomedical applications, from anatomical and functional mapping to gene expression, silencing, and editing
Stereoselective handling of perhexiline:Implications regarding accumulation within the human myocardium
Purpose: Perhexiline is a prophylactic anti-ischaemic agent with weak calcium antagonist effect which has been increasingly utilised in the management of refractory angina. The metabolic clearance of perhexiline is modulated by CYP2D6 metaboliser status and stereoselectivity. The current study sought to (1) determine whether the acute accumulation of perhexiline in the myocardium is stereoselective and (2) investigate the relationship between duration of short-term therapy and the potential stereoselective effects of perhexiline within myocardium. Method: Patients (n = 129) from the active arm of a randomised controlled trial of preoperative perhexiline in cardiac surgery were treated with oral perhexiline for a median of 9 days. Correlates of atrial and ventricular concentrations of enantiomers were sought via univariate followed by multivariate analyses. Results: Myocardial uptake of both (+) and (−) perhexiline was greater in ventricles than in atria, and there was more rapid clearance of (−) than (+) perhexiline. The main determinants of atrial uptake of both (+) and (−) perhexiline were the plasma concentrations [(+) perhexiline: β = −0.256, p = 0.015; (−) perhexiline: β = −0.347, p = 0.001] and patients’ age [(+) perhexiline: β = 0.300, p = 0.004; (−) perhexiline: β = 0.288, p = 0.005]. Atrial uptake of (+) enantiomer also varied directly with duration of therapy (β = 0.228, p = 0.025), while atrial uptake of (−) perhexiline varied inversely with simultaneous heart rate (β = −0.240, p = 0.015). Conclusion: (1) Uptake of both perhexiline enantiomers into atrium is greater with advanced age and displays evidence of both saturability and minor stereoselectivity. (2) Atrial uptake of (−) perhexiline may selectively modulate heart rate reduction
Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial
Background
Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy
- …